Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

OBJECTIVE:

I. To identify potential genetic modifiers of breast cancer risk in women who are carriers of the breast cancer susceptibility genes, BRCA1/2, by collecting data and genetic information from GOG-0199 and contributing it to the Consortium of Investigators of Modifiers of BRCA-Associated Breast Cancer (CIMBA), an international consortium of clinical cancer genetics investigators.

OUTLINE: This is a multicenter study. Patients are stratified by study, country of residence, ethnicity, and birth cohort. Joint analyses of BRCA1 and BRCA2 mutation carriers are further stratified by mutation.

Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., single nucleotide polymorphisms \[SNPs\]) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the Consortium of Investigators of Modifiers of BRCA-Associated Breast Cancer (CIMBA) Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.

• Laboratory Biomarker Analysis (Other): Correlative studies

Primary outcomes

• Identification of potential genetic modifiers of breast cancer risk [Up to 2 years]

Sex: Female, ages: 18 Years to 80 Years

Inclusion Criteria:

* Women with or without a personal history of breast cancer prior to enrollment in Gynecologic Oncology Group (GOG)-0199

  * Known currently to be BRCA1/2 mutation carrier either by confirmed outside report or by research testing

    * No BRCA1/2 mutation-negative or mutation-unknown status
* Enrolled on clinical trial GOG-0199 AND meets the following criteria:

  * Completed baseline questionnaire (BQ-199)
  * Provided information on previous breast cancer history, including date of diagnosis
  * Provided complete data from the DNA analysis on the genetic variants of interest
* Available DNA samples for analysis
* Hormone receptor status not specified
* Pre- or post-menopausal status

• Mark Greene, Principal investigator, Gynecologic Oncology Group

NIH grants: U10CA101165